These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30489482)

  • 1. Prognostic role of NRAS isoforms in Chinese melanoma patients.
    Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
    Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients.
    Yu J; Xu L; Yan J; Yu J; Wu X; Dai J; Guo J; Kong Y
    Clin Exp Med; 2020 May; 20(2):299-311. PubMed ID: 32172429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.
    Duggan MC; Regan-Fendt K; Olaverria Salavaggione GN; Howard JH; Stiff AR; Sabella J; Latchana N; Markowitz J; Gru A; Tridandapani S; Eisfeld AK; de la Chapelle A; Carson WE
    Melanoma Res; 2019 Oct; 29(5):491-500. PubMed ID: 31116161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
    Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
    Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
    J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
    Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
    Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRAS mutations in primary and metastatic melanomas of Japanese patients.
    Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
    Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
    Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
    Front Immunol; 2021; 12():691032. PubMed ID: 34290710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers.
    Noma IHY; Carvalho LADC; Camarena DEM; Silva RO; Moraes Junior MO; de Souza ST; Newton-Bishop J; Nsengimana J; Maria-Engler SS
    Biomed Pharmacother; 2024 Aug; 177():116953. PubMed ID: 38955087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.